Faeth Therapeutics (FTH) Capital Leases (2020 - 2025)

Faeth Therapeutics (FTH) has reported Capital Leases for 6 consecutive years, with $4000.0 the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, Capital Leases fell 98.94% year-over-year to $4000.0; the trailing twelve-month figure through Jun 2025 stood at $4000.0 (down 98.94% YoY), and the FY2024 full-year result was $98000.0, down 87.24% from the prior year.
• Capital Leases eased to $4000.0 in Q2 2025 per FTH's latest filing, from $35000.0 in the prior quarter.
• Across five years, Capital Leases topped out at $1.8 million in Q1 2022 and bottomed at $4000.0 in Q2 2025.
• Historically, Capital Leases has averaged $935066.7 across 5 years, with a median of $962000.0 in 2023.
• The sharpest annual moves came in 2021 and 2025: Capital Leases jumped 1846.51% in 2021, then slumped 98.94% in 2025.
• Over 5 years, Capital Leases stood at $1.7 million in 2021, then decreased by 5.68% to $1.6 million in 2022, then slumped by 51.36% to $768000.0 in 2023, then plunged by 87.24% to $98000.0 in 2024, then sank by 95.92% to $4000.0 in 2025.
• According to Business Quant data, Capital Leases over the past three periods registered $4000.0, $35000.0, and $98000.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.